Bullous Pemphigoid Managed With Methotrexate

BY NANCY WALSH

New York Bureau

BY BRUCE JANCIN

Denver Bureau

KYOTO, JAPAN — The annual incidence of both bullous pemphigoid and pemphigus vulgaris has climbed steadily over the past decade in the United Kingdom for reasons unknown, according to a study of more than 1,000 patients.

The mortality associated with these autoimmune diseases may have been underestimated in the past, based upon the results of Dr. Sinéad Langan’s large, population-based study presented at an international investigative dermatology meeting.

‘People with bullous pemphigoid are twice as likely to die and those with pemphigus vulgaris are three times as likely to die as [are] matched controls,’ said Dr. Langan of the University of Nottingham (England).

Her study of The Health Improvement Network (THIN)—a large, population-based database of computerized primary care medical records—identified 868 patients diagnosed with bullous pemphigoid (BP) and 139 diagnosed with pemphigus vulgaris (PV) during 1996-2006. Each patient was matched by age and gender with four controls from the same general practice.

She undertook the study because, despite the substantial morbidity and mortality associated with these autoimmune diseases, little is known about their epidemiology. For example, there are only two previously published studies addressing PV mortality; one, from the Middle East, reported a 1-year mortality of 5%, while a 1975 U.S. study found a 50% 1-year mortality, she said. The reported BP mortality has cut a similarly wide swath.

The incidence of BP in the new U.K. study climbed with advancing age, peaking in a group aged 80-84 years. The median age at presentation was 80 years, and 62% of affected patients were women.

PV incidence showed a bimodal distribution, with peaks at ages 45-49 years and a second, larger one at 62-66 years. The median age at presentation was 80 years, with a peak at ages 45-49 years, and a second, larger one at 60-64 years. Median age at presentation was 71 years, and two-thirds of patients were women.

The usual regimen involved an initial dosage of 5 mg/week of methotrexate, with topical betamethasone dipropionate applied twice daily until the disease was controlled. If necessary, methotrexate dosage was increased by 2.5 mg/week.

If symptoms persisted despite methotrexate treatment, prednisone was added in doses of 10-20 mg/day, and if methotrexate could not be given because of anemia, liver disease, or renal failure, prednisone was given alone.

Between 1999 and 2001, 138 patients whose mean age was 81 years were diagnosed with BP. Of these, 57% were women, 31% had mild disease, 38% had moderate disease, and 11% had severe disease.

Methotrexate treatment was initiated in 98 (71%), with a median weekly dosage of 5 mg. Among these patients, 61 continued on methotrexate monotherapy (group 1) and had a mean cumulative dose of 280 mg.

Among patients who received methotrexate, 37 were treated with prednisone (group 2). The median weekly dosage of methotrexate in this group was 6 mg, and the median cumulative dose was 440 mg.

Forty-three patients did not receive any high-dose prednisone and had a mean cumulative dose of 12 mg and with a median cumulative dose of 4,000 mg (group 3). The other 25 patients who did not receive methotrexate (group 4) had mild disease and were managed with topical betamethasone gel alone.

Median follow-up was 26 months. At 24 months, the BP mortality rates were 4% in group 1, 13% in group 2, 0% in group 3, and 83% in group 4 (Arch. Dermatol. 2008;144:612-16).

Mortality in BP is considerable, with previous reports estimating a 1-year mortality ranging from 10% to 41%, according to the researchers. In this series, 2-year survival was 65%, 67%, 47%, and 52% in the four groups, respectively, and there was a tendency toward better survival for the methotrexate-treated patients, with median survival times of 38 and 24 months in groups 1 and 2, respectively.

Only one patient in this series developed anemia, and although elevated liver enzymes were seen on occasion during the first weeks of therapy, normalization usually followed within 4-6 weeks. They did not perform pre-treatment liver biopsies.

They researchers noted that they are also developing a BP quality register and biobank to enable further follow-up and to provide further information. They had no conflicts of interest to disclose.

Bullous Pemphigoid and Pemphigus Vulgaris Rates Climbing in U.K.

BY NANCY WALSH

New York Bureau

L

ow-dose methotrexate combined with topical betamethasone dipropionate was a safe and effective treatment for bullous pemphigoid in a retrospective study conducted by Dr. Petra Kjellman and colleagues. For the past 50 years, glucocorticoids have been the mainstay of treatment for bullous pemphigoid (BP), but the high doses of these drugs that are typically used to control inflammation are poorly tolerated, particularly among the elderly, who are most commonly affected, according to the researchers.

To minimize the adverse effects of glucocorticoids, which include sepsis, pneumonia, gastrointestinal tract bleeding, diabetes, and osteoporosis, other immunosuppressants also have been tried as steroid-sparing agents in BP, but few controlled trials have been done, they noted.

For the past decade, Dr. Kjellman and colleagues from the department of dermatology and venerology, Karolinska University Hospital, Stockholm, have preferentially used methotrexate for BP patients, with prednisone if needed or if methotrexate could not be given or tolerated.

Autoantibodies for Bullous Pemphigoid Found in Unaffected

KYOTO, JAPAN — More than 7% of individuals without any form of autoimmune disease possess elevated serum bullous pemphigoid 180 and/or BP230 autoantibodies on the commercially available enzyme-linked immunosorbent assay, according to testing of stored serum from 370 people.

These autoantibodies have been considered diagnostic for bullous pemphigoid, the most common cutaneous autoimmune bullous disorder, but that is clearly not the case, Dr. Ntineka J. Comfere of the Mayo Clinic in Rochester, Minn., reported at an international investigative dermatology meeting.

‘I think there’s not one test we can clearly rely on to make the diagnosis. What we’ve concluded at the Mayo Clinic is disease confirmation requires a correlation of multiple measures, including the clinical pattern, the presentation of disease, routine histopathology, and both direct and indirect immunofluorescence studies, as well as the ELISA [enzyme-linked immunosorbent assay], in order to ensure the highest diagnostic accuracy. Clearly, one cannot rely solely on the ELISA,’ she said.

Dr. Comfere and her associates examined the prevalence of circulating BP180 and BP230 autoantibodies across the age spectrum of individuals who did not have bullous pemphigoid or any other autoimmune disease. They tested stored serum from patients aged 20 years to more than 90 years.

A positive test for one or both autoantibodies, defined by the manufacturer as a level of nine units or more, was detected in 7% of subjects. The prevalence did not vary by decade of life or by gender. Moreover, the geometric mean titer also remained similar across the decades, she said at a meeting of the European Society for Dermatological Research, the Japanese Society for Investigative Dermatology, and the Society for Investigative Dermatology.

Audience members raised the possibility that the presence of circulating autoantibodies in asymptomatic individuals might precede clinical manifestations of the disease, but the finding that prevalence of the autoantibodies was similar across the decades rather than peaking in the elderly argues against this, Dr. Comfere noted.

The role of these autoantibodies in initiating and perpetuating the disease process remains unclear, she added. It’s possible that the development of clinical bullous pemphigoid requires exogenous factors in susceptible individuals.

—Bruce Jancin

Autoimmunity/Connective Tissue 53